Binimetinib Patent Expiration
Binimetinib is Used for treating melanoma and non-small cell lung cancer in combination with encorafenib for patients with a BRAF mutation. It was first introduced by Array Biopharma Inc
Binimetinib Patents
Given below is the list of patents protecting Binimetinib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Mektovi | US10005761 | Compounds and compositions as protein kinase inhibitors | Aug 27, 2030 | Array Biopharma Inc |
| Mektovi | US7777050 | N3 alkylated benzimidazole derivatives as MEK inhibitors | Mar 13, 2025 | Array Biopharma Inc |
| Mektovi | US8178693 | N3 alkylated benzimidazole derivatives as MEK inhibitors |
Mar 13, 2023
(Expired) | Array Biopharma Inc |
| Mektovi | US8193229 | Method of treatment using N3 alkylated benzimidazole derivatives as MEK inhibitors |
Mar 13, 2023
(Expired) | Array Biopharma Inc |
| Mektovi | US8513293 | Methods of treating a hyperproliferative disorder or inhibiting cell growth in a mammal |
Mar 13, 2023
(Expired) | Array Biopharma Inc |
| Mektovi | US9314464 | Compounds and compositions as protein kinase inhibitors | Jul 04, 2031 | Array Biopharma Inc |
| Mektovi | US9562016 | Preparation of and formulation comprising a MEK inhibitor | Oct 18, 2033 | Array Biopharma Inc |
| Mektovi | US9593100 | Compounds and compositions as protein kinase inhibitors | Aug 27, 2030 | Array Biopharma Inc |
| Mektovi | US9598376 | Preparation of and formulation comprising a MEK inhibitor | Oct 18, 2033 | Array Biopharma Inc |
| Mektovi | US9850229 | Compounds and compositions as protein kinase inhibitors | Aug 27, 2030 | Array Biopharma Inc |
| Mektovi | US9980944 | Preparation of and formulation comprising a MEK inhibitor | Oct 18, 2033 | Array Biopharma Inc |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳